Small molecule · developed by NeuroSense Therapeutics
PrimeC is an extended release fixed dose combination of ciprofloxacin and celecoxib. It is studied in pharmacokinetics and Alzheimer disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06185543 | Phase 2 | Alzheimer Disease | Terminated | NRSN |
| NCT05436678 | Phase 1 | Pharmacokinetics | Completed | NRSN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer DiseasePharmacokinetics
Updated Oct 25, 2026. Something wrong or missing? Report it on the NRSN page.
See NRSN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NRSN catalysts and pipeline →